NCT02469519

Brief Summary

This trial hopes to prospectively evaluate the impact of one versus two courses of antenatal steroids on the incidence of major neonatal morbidity in pregnant women with pre-labor premature rupture of the membranes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
194

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Mar 2016

Longer than P75 for phase_2

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 5, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 11, 2015

Completed
9 months until next milestone

Study Start

First participant enrolled

March 3, 2016

Completed
6.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 15, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2022

Completed
Last Updated

December 15, 2022

Status Verified

December 1, 2022

Enrollment Period

6.5 years

First QC Date

June 5, 2015

Last Update Submit

December 14, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Composite Neonatal Morbidity

    Composite Neonatal Morbidity includes any one or more of the following: respiratory distress syndrome, bronchopulmonary dysplasia, severe intraventricular hemorrhage, periventricular leukomalacia, proven sepsis, necrotizing enterocolitis, or neonatal death.

    from birth through the first 28 days of life

Secondary Outcomes (11)

  • Gestational age of baby

    measured within the first 24 hours following birth.

  • Baby's birth weight

    measured within the first 24 hours following birth

  • Intrauterine growth restriction (IUGR)

    anytime during the pregnancy prior to birth (~ 9 months of pregnancy)

  • Baby's Head Circumference

    measured within the first 24 hours following birth

  • Newborn Mechanical Ventilatory days

    measured from birth to 28 days following birth

  • +6 more secondary outcomes

Study Arms (2)

Betamethasone - ACTIVE

EXPERIMENTAL

Booster Course of Antenatal Steroids consists of Betamethasone \[12 mg intramuscular injection, 24 hours apart X 2 doses\] or if unavailable may give Dexamethasone \[6 mg intramuscularly 12 hours apart x 4 doses\]

Drug: Betamethasone - ACTIVE

normal saline - PLACEBO

PLACEBO COMPARATOR

Normal saline of equivalent volume given intramuscularly at the equivalent dosing regimes listed in experimental arm.

Other: Normal Saline - PLACEBO

Interventions

antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.

Also known as: antenatal corticosteroid, dexamethasone
Betamethasone - ACTIVE

normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses

Also known as: NS
normal saline - PLACEBO

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants age 18 years or older
  • w0d to 32w6d weeks gestation
  • Singleton pregnancy
  • Received first course of ACS at or prior to 31w6d gestation
  • Began first course of ACS at least 7 days ( =/\> 168 hours) prior to randomization
  • Expectant management planned
  • Premature Ruptured membranes (PROM) before onset of labor

You may not qualify if:

  • Known major fetal anomalies
  • Multiple gestation
  • Not a candidate for expectant management
  • Clinical chorioamnionitis (two or more of the following: temperature \> 38.0 degrees centigrade; uterine tenderness; foul smelling vaginal discharge or amniotic fluid; maternal tachycardia \>100 bpm; fetal tachycardia \>160 bpm; maternal White Blood Cell (WBC) count \>20 X 109/L; C-Reactive Protein (CRP) \> 5.9
  • Already receiving corticosteroids for another condition
  • Any contraindications to the maternal use of corticosteroids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

University of South Alabama Medical Center

Mobile, Alabama, 36617, United States

Location

Phoenix Perinatal Associates

Phoenix, Arizona, 85014, United States

Location

Long Beach Memorial Medical Center

Long Beach, California, 90801-1428, United States

Location

Good Samaritan Hospital

San Jose, California, 95008, United States

Location

Presbyterian/St Luke's Hospital

Denver, Colorado, 80218, United States

Location

Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States

Location

Lousiana State University Health Science

Shreveport, Louisiana, 60612, United States

Location

University of Tennessee Medical Center

Knoxville, Tennessee, 37920, United States

Location

Swedish Medical Center

Seattle, Washington, 98122-4307, United States

Location

Related Publications (1)

  • Porreco R, Garite TJ, Combs CA, Maurel K, Huls CK, Baker S, Fortner KB, Longo SA, Nageotte M, Lewis D, Tran L; Obstetrix Collaborative Research Network. Booster course of antenatal corticosteroids after preterm prelabor rupture of membranes: a double-blind randomized trial. Am J Obstet Gynecol MFM. 2023 May;5(5):100896. doi: 10.1016/j.ajogmf.2023.100896. Epub 2023 Feb 14.

MeSH Terms

Conditions

Premature Birth

Interventions

Dexamethasone

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Study Officials

  • Richard Porreco, MD

    Pediatrix

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 5, 2015

First Posted

June 11, 2015

Study Start

March 3, 2016

Primary Completion

August 15, 2022

Study Completion

October 31, 2022

Last Updated

December 15, 2022

Record last verified: 2022-12

Data Sharing

IPD Sharing
Will not share

Locations